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Abstract
The relationship between circulating total bilirubin and incident non-alcoholic fatty liver disease (NAFLD) is uncertain. We 
aimed to assess the association of total bilirubin with the risk of new-onset NAFLD and investigate any causal relevance 
to the association using a Mendelian randomization (MR) study. Plasma total bilirubin levels were measured at baseline in 
the PREVEND prospective study of 3824 participants (aged 28–75 years) without pre-existing cardiovascular disease or 
NAFLD. Incident NAFLD was estimated using the biomarker-based algorithms, fatty liver index (FLI) and hepatic steatosis 
index (HSI). Odds ratios (ORs) (95% confidence intervals) for NAFLD were assessed. The genetic variant rs6742078 located 
in the UDP-glucuronosyltransferase (UGT1A1) locus was used as an instrumental variable. Participants were followed up 
for a mean duration of 4.2 years. The multivariable adjusted OR (95% CIs) for NAFLD as estimated by FLI (434 cases) was 
0.82 (0.73–0.92; p = 0.001) per 1 standard deviation (SD) change in  loge total bilirubin. The corresponding adjusted OR 
(95% CIs) for NAFLD as estimated by HSI (452 cases) was 0.87 (0.78–0.97; p = 0.012). The rs6742078 variant explained 
20% of bilirubin variation. The ORs (95% CIs) for a 1 SD genetically elevated total bilirubin level was 0.98 (0.69–1.38; 
p = 0.900) for FLI and 1.14 (0.81–1.59; p = 0.451) for HSI. Elevated levels of total bilirubin were not causally associated with 
decreased risk of NAFLD based on MR analysis. The observational association may be driven by biases such as unmeasured 
confounding and/or reverse causation. However, due to low statistical power, larger-scale investigations are necessary to 
draw definitive conclusions.
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Introduction
Circulating total bilirubin has been consistently shown to 
be inversely and independently associated with adverse 
cardiometabolic outcomes such as cardiovascular disease 
(CVD), hypertension and type 2 diabetes [1–3]. Though a 
causal association has been demonstrated for total bilirubin 
and type 2 diabetes [4], there is no strong evidence for a 
causal association between total bilirubin levels and CVD 
[5, 6]. Nonalcoholic fatty liver disease (NAFLD), emerging 
as the most common cause of chronic liver disease in the 
developed world [7], is a cardiometabolic condition which 
is characterized by hepatic steatosis with varying degrees 
of necroinflammation and fibrosis [7]. In the absence of 
the reference standard—liver biopsy [8], the diagnosis of 
NAFLD is commonly based on (1) imaging techniques 
[i.e., ultrasonography, computed tomography (CT) scan, or 
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magnetic resonance imaging (MRI)] confirming the pres-
ence of fat infiltration of the liver, (2) exclusion of other 
liver diseases of other aetiology and (3) in the absence of 
substantial alcohol intake [9]. Due to the high costs associ-
ated with these imaging techniques and their unsuitability 
for use in large-scale population-based studies, a number of 
biomarker-based algorithms have been developed to aid the 
diagnosis of NAFLD. The fatty liver index (FLI) [10] and 
the hepatic steatosis index (HSI) [11] are based on easily 
accessible variables and have been reported to have good 
diagnostic accuracies for NAFLD [10–12].
Given the existence of a strong link between total biliru-
bin and adverse cardiometabolic outcomes, which has been 
attributed to the antioxidant [13, 14], anti-inflammatory [15] 
and antiatherogenic properties of bilirubin; [16] there have 
been suggestions that circulating total bilirubin might also be 
associated with a reduced risk of NAFLD. Indeed, a number 
of observational studies have reported on the associations 
between bilirubin and NAFLD over recent years. However, 
these were based on cross-sectional or case–control study 
designs limited by lack of temporality, paediatric popula-
tions, selected patients with pre-existing disease or were 
unable to demonstrate associations specifically between total 
circulating bilirubin and NAFLD risk [17–22]. Therefore 
uncertainty remains regarding the nature and magnitude 
of the prospective association between total bilirubin and 
NAFLD. With the ongoing debate on the potential value 
of using circulating total bilirubin to prevent and treat car-
diometabolic outcomes [23–25], it will be clinically useful 
if circulating total bilirubin is shown to contribute to the 
development of NAFLD. In this context, we aimed to quan-
tify the nature and magnitude of the prospective association 
between total bilirubin and the risk of NAFLD (as estimated 
by these two indices—FLI and HSI) in a general population 
sample who were free from pre-existing disease (NAFLD, 
CVD, and malignancy) at baseline. Since observational 
epidemiological studies are beset by several biases such as 
residual confounding, reverse causation, and regression dilu-
tion [26–29], we utilized a Mendelian randomisation (MR) 
to assess if there is a causal relevance to the association 
using the well-known rs6742078 variant in the UGT1A1 
gene [6, 30].
Materials and methods
Study population
We conducted this study according to STROBE (STrength-
ening the Reporting of OBservational studies in Epidemiol-
ogy) guidelines for reporting observational studies in epi-
demiology (“Appendix 1”) [31]. Participants for the current 
analysis were part of the ongoing Prevention of Renal and 
Vascular End-stage Disease (PREVEND) study, a large-
scale general population-based observational cohort study 
which began in 1997 in the Netherlands. The PREVEND 
study was designed to investigate the natural course of uri-
nary albumin excretion and its relationship to renal and CVD 
progression. The study design and recruitment procedures 
have been described in detail in several previous reports [2, 
32]. Briefly, 8592 inhabitants aged 28–75 years living in 
the city of Groningen, the Netherlands were recruited into 
the PREVEND study with baseline measurements per-
formed between 1997 and 1998. For the present analysis, we 
excluded participants (1) with a prevalent history of CVD, 
renal disease, malignancy, or NAFLD (for the analysis of 
FLI outcome, participants with prevalent NAFLD as meas-
ured by FLI were excluded and vice versa for HSI) and (2) 
with excessive alcohol use (defined as four or more drinks 
per day), which left a cohort of 3824 participants (based on 
FLI) with non-missing information on total bilirubin levels, 
relevant covariates, and outcomes. Of these participants, 
1610 individuals had complete phenotypic and genotypic 
data. The PREVEND study complies with the Declaration 
of Helsinki and was approved by the medical ethics com-
mittee of the University Medical Center Groningen. All par-
ticipants provided written informed consent for voluntary 
participation.
Risk factor assessment
For the assessment of baseline data on sociographic charac-
teristics, physical measurements, medical history, and use 
of medication, participants completed two outpatient visits. 
Further information on medication use was complemented 
using data from all community pharmacies in the city of 
Groningen and this covers complete information on drug 
use in 95% of PREVEND participants. Venous blood was 
obtained from participants after an overnight fast and 15 min 
of rest. Plasma samples were prepared by centrifugation at 
4 °C. Blood lipids (total cholesterol, high-density lipopro-
tein cholesterol (HDL-C), and triglycerides (TGs)), high 
sensitivity C-reactive protein (hsCRP), serum creatinine, 
and serum cystatin C were measured using standard labora-
tory protocols previously described [33–35]. Total bilirubin 
was measured using a colorimetric assay (2,4-dicholorani-
line reaction; Merck MEGA, Darmstadt, Germany), with 
the detection limit being 1.0 µmol/L. The inter-assay coef-
ficients of variation were 3.8% and 2.9% in the lower nor-
mal and higher normal range respectively. The mean of two 
24-h urine collections was used to estimate urinary albu-
min excretion (UAE) and its concentration determined by 
nephelometry (BNII; Dade Behring Diagnostic, Marburg, 
Germany). Serum liver aminotransferase (alanine ami-
notransferase, ALT and aspartate aminotransferase, AST) 
activities were measured using the standardized kinetic 
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method with pyridoxal phosphate activation (Roche Modu-
lar P; Roche Diagnostics, Mannheim, Germany). Serum 
gamma-glutamyltransferase (GGT) activity was measured by 
an enzymatic colorimetric method (Roche Modular P; Roche 
Diagnostics, Mannheim, Germany). Estimated glomerular 
filtration rate (eGFR), was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) 
combined creatinine-cystatin C equation [36]. Body mass 
index (BMI) was estimated by dividing weight measured in 
kilograms by the square of height in meters.
NAFLD ascertainment
The FLI was calculated based on the report by Bedogni et al. 
[10] using the following formula:
The FLI ranges from 0 to 100, with FLI < 30 ruling out 
(sensitivity = 87%) and FLI ≥ 60 ruling in fatty liver disease 
(specificity = 86%) with a good diagnostic accuracy of 0.84 
(95% CI 0.81–0.87).
The HSI was estimated using the following formula as 
reported by Lee et al.: [11]
Genotyping
Genotyping was performed using Illumina Human-
CytoSNP-12 arrays. SNPs were called using Illumina 
Genome Studio software. SNPs were excluded with minor 
allele frequency < 0.01, call rate < 0.95, or deviation from 
Hardy–Weinberg equilibrium (p < 1×10 − 5). The rs6742078 
SNP was a suitable instrumental variable for the present 
analyses, given its robust specificity for circulating total 
bilirubin levels (explaining up to 45% of the variation in 
circulating bilirubin levels [37]) and its use in previous stud-
ies to assess the causal relevance of total bilirubin to several 
disease outcomes [5, 6, 30].
Statistical analyses
Observational analyses
Skewed variables (total bilirubin, ALT, AST, TGs, hsCRP, 
and UAE) were natural log-transformed to approximate nor-
mal distributions. Descriptive analyses were used to sum-
marize baseline characteristics of participants overall and 
according to NAFLD outcomes. Partial correlation coeffi-
cients adjusted for age and sex were calculated to assess 
FLI = [e(0.953×ln (TG)+0.139×BMI+0.718×ln (GGT)+0.053×WC−15.745)]∕[1 + e(0.953×ln (TG)+0.139×BMI+0.718×ln (GGT)+0.053×WC−15.745)] × 100
HSI = 8 × ALT∕AST ratio + BMI (+2, if diabetes; + 2, if female);
with HSI values < 30 and > 36 ruling out and ruling in fatty liver respectively.
cross-sectional associations of total bilirubin levels with 
risk markers for NAFLD. Logistic regression was used to 
examine the association of total bilirubin with new-onset 
NAFLD as measured by FLI or HSI (observed effect of 
bilirubin on NAFLD). The odds ratio (OR) with 95% confi-
dence intervals (CIs) for the risk of NAFLD was calculated 
per 1 standard deviation, SD higher  loge total bilirubin lev-
els. In subsidiary analyses, total bilirubin was modeled as 
tertiles defined according to its baseline distribution. The 
SD of baseline  loge total bilirubin level was 0.42 (equiva-
lent to 1.5-fold higher circulating total bilirubin level, as 
 e0.42 = 1.52). Odds ratios were progressively adjusted for in 
four models: (Model 1) age and sex; (Model 2) plus smok-
ing status, systolic blood pressure (SBP), total cholesterol, 
and HDL-C; (Model 3) plus alcohol consumption, glucose, 
eGFR, and UAE; and (Model 4) plus hsCRP. Confound-
ers were selected based on their known associations with 
NAFLD and observed associations with total bilirubin using 
the available data [38] and evidence from previous research 
[1, 2]. We used interaction tests to assess statistical evidence 
of effect modification by sex on the association. To minimise 
bias due to potential reverse causation, we carried out sen-
sitivity analyses that excluded participants with a history of 
diabetes at baseline, participants on regular statin medication 
or participants with potential Gilbert’s syndrome (defined 
as defined as total bilirubin > 34.2 µmol/L, AST < 80 IU/L, 
ALT < 80 IU/L, and GGT < 80 IU/L) [1].
Mendelian randomization
To assess for pleiotropy, we tested whether rs6742078 was 
associated with relevant risk markers which might confound 
the relationship between total bilirubin and NAFLD. We 
assessed the association between rs6742078 and  loge total 
bilirubin using linear regression under the assumption of 
an additive genetic model, with adjustment for covariates 
used in the observational analysis between total bilirubin and 
NAFLD. This analysis provided the number of SDs above 
 loge total bilirubin per each copy increase in number of the 
T allele. In order to estimate the causal effect of bilirubin 
on NAFLD, we used the two-stage least squares (2SLS) 
method. The first stage of the 2SLS method is to examine the 
association between rs6742078 and total bilirubin by means 
of linear regression (model 1) and then saving the predicted 
values and the residuals. In the second stage, the predicted 
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values of total bilirubin from model 1 are used as covariates, 
with NAFLD as a dependent variable in a logistic regres-
sion, which provides the MR estimate. Estimates of power 
for the MR analysis on NAFLD employed an online power 
calculator ([http:/cnsgenomics.com/shiny/mRnd/]). We used 
the genetic sample size and case/control ratios together with 
the proportion of variance of total bilirubin explained by 
rs6742078. Using PREVEND data, we had 20% power to 
detect a causal association of bilirubin on NAFLD, similar 
in magnitude to the fully adjusted observational OR of 0.82. 
All statistical analyses were conducted using Stata version 
15 (Stata Corp, College Station, Texas, USA).
Table 1  Baseline characteristics and cross-sectional correlates of total bilirubin
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomeru-
lar filtration rate (as calculated using the Chronic Kidney Disease Epidemiology Collaboration combined creatinine-cystatin C equation), GGT 
gamma-glutamyltransferase, HDL-C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, Ref reference, SD standard 
deviation, SBP systolic blood pressure, UAE urinary albumin excretion
a Partial correlation coefficients between  loge total bilirubin and each of the row variables adjusted for age and sex
b Percentage change in total bilirubin levels per 1 SD increase in the row variable (or for categorical variables, the percentage difference in mean 
total bilirubin levels for the category versus the reference) adjusted for age and sex
Asterisks indicate the level of statistical significance: * p < 0.05; ** p < 0.01; *** p < 0.001
Overall (N = 3824)
Mean (SD) or 
median (IQR) or 
n (%)
Partial correlation
r (95% CI)a
Percentage difference (95% CI) in total bilirubin levels 
per 1 SD higher or compared to reference category of 
 correlateb
Total bilirubin (µmol/l) 7 (5–9) – –
Sex
 Female 2273 (59.4) – Ref
 Male 1551 (40.6) – 28% (25, 31)***
Questionnaire
Age at survey (years) 47 (12) − 0.02 (− 0.06, 0.01) − 1% (− 2, 0)
History of diabetes
 No 3801 (99.4) – Ref
 Yes 23 (0.6) – − 8% (− 22, 8)
Smoking status
 Non-smokers 1309 (34.2) – Ref
 Current and former smokers 2515 (65.8) – − 12% (− 14, − 9)***
Alcohol consumption
 Non-consumers 886 (23.2) – Ref
 Current consumers 2938 (76.8) – 3% (0, 7)*
Physical measurements
BMI (kg/m2) 24.4 (2.8) − 0.11 (− 0.15, − 0.09)*** − 5% (− 6, − 3)***
Waist circumference (cm) 82.6 (9.5) − 0.08 (− 0.11, − 0.05)*** − 4% (− 5, − 2)***
SBP (mmHg) 123 (18) − 0.01 (− 0.04, 0.02) − 1% (− 2, 1)
DBP (mmHg) 71 (9) − 0.03 (− 0.06, 0.00) − 1% (− 3, 0)
Lipid, metabolic, inflammatory, liver, and renal markers
Total cholesterol (mmol/l) 5.44 (1.07) − 0.09 (− 0.13, − 0.06)* − 4% (− 5, − 3)*
HDL-C (mmol/l) 1.43 (0.39) 0.10 (0.07, 0.13)*** 5% (3, 6)***
Triglycerides (mmol/l) 0.98 (0.75–1.31) − 0.15 (− 0.18, − 0.12)*** 6% (− 7, − 5)***
Glucose (mmol/l) 4.60 (0.73) − 0.05 (− 0.08, − 0.02)* − 2% (− 3, − 1)*
GGT (U/L) 19 (14–27) − 0.02 (− 0.05, 0.01) − 1% (− 2, 0)
ALT (U/L) 18 (14–23) 0.03 (0.00, 0.06)* 1% (0, 3)*
AST (U/L) 23 (20–27) 0.09 (0.06, 0.13)*** 4% (3, 6)***
hsCRP (mg/l) 0.90 (0.41–2.12) − 0.24 (− 0.27, − 0.21)*** − 9% (− 10, − 8)***
eGFR (ml/min/1.73 m2) 90.8 (15.0) − 0.01 (− 0.04, 0.02) − 0% (− 2, 1)
UAE (mg/24 h) 8.14 (5.91–12.53) − 0.01 (− 0.04, 0.03) 1% (− 1, 2)
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Results
Baseline characteristics and correlates of total 
bilirubin
Baseline descriptive characteristics of study participants 
as well as cross-sectional correlates of total bilirubin are 
shown in Table 1. The overall mean age of participants at 
study entry was 47 (SD 12) years and 40.6% were women. 
The mean (SD) of  loge total bilirubin level was 1.96 (0.42) 
µmol/l. There were weak and inverse correlations of  loge 
total bilirubin levels with physical measures (BMI and waist 
circumference), lipids (total cholesterol and TGs), and glu-
cose. There were weak positive correlations with HDL-C 
and the liver aminotransferases. There was an inverse cor-
relation with  loge hsCRP (r = − 0.24). Baseline total bilirubin 
levels were higher by 28% in men compared with women. 
The levels were lower by 12% in the combined group of 
current and former smokers compared with non-current 
smokers (Table 2). “Appendices 2–3” show baseline char-
acteristics according to the development of NAFLD. Except 
for history of diabetes and smoking status, there were sig-
nificant differences in baseline clinically relevant subgroups 
and levels of risk markers between participants who did and 
did not develop NAFLD (for both indices) during follow-up. 
Total bilirubin levels and risk of incident NAFLD
During a mean (SD) follow-up of 4.2 (0.4) years, 434 and 
452 cases of NAFLD as estimated by FLI and HSI respec-
tively, were recorded. The associations between total bil-
irubin and NAFLD as estimated by the FLI are reported 
Table 2  Association of baseline total bilirubin with incident NAFLD as measured by FLI
2420 participants with prevalent NAFLD as measured by FLI were excluded
CI confidence interval, FLI fatty liver index, NAFLD non-alcoholic fatty liver disease, OR odds ratio, SD standard deviation, T tertile
Model 1: Age and sex
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol
Model 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and  loge urinary albumin excretion
Model 4: Model 3 plus  loge high-sensitivity C-reactive protein
Total 
bilirubin level 
(µmol/l)
Events/total Model 1 Model 2 Model 3 Model 4
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Per 1 SD 
increase
434/3824 0.72 (0.64 to 
0.80)
< 0.001 0.78 (0.69 to 
0.87)
< 0.001 0.77 (0.69 to 
0.87)
< 0.001 0.82 (0.73 to 
0.92)
0.001
T1 (0.95–6) 208/1627 Ref. Ref. Ref. Ref.
T2 (7, 8) 116/1024 0.70 (0.55 to 
0.90)
0.006 0.85 (0.65 to 
1.10)
0.209 0.85 (0.66 to 
1.11)
0.232 0.92 (0.71 to 
1.20)
0.536
T3 (≥ 9) 110/1173 0.51 (0.39 to 
0.66)
< 0.001 0.62 (0.47 to 
0.81)
< 0.001 0.61 (0.47 to 
0.80)
< 0.001 0.69 (0.52 to 
0.91)
0.008
Table 3  Association of baseline total bilirubin with incident NAFLD as measured by HSI
2801 participants with prevalent NAFLD as measured by HSI were excluded
CI confidence interval, HSI hepatic steatosis index, NAFLD non-alcoholic fatty liver disease, OR odds ratio, SD standard deviation, T tertile
Model 1: Age and sex
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol
Model 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and  loge urinary albumin excretion
Model 4: Model 3 plus  loge high-sensitivity C-reactive protein
Total bilirubin 
level (µmol/l)
Events/total Model 1 Model 2 Model 3 Model 4
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Per 1 SD 
increase
452/3570 0.79 (0.72 to 
0.88)
< 0.001 0.83 (0.75 to 
0.93)
0.001 0.84 (0.75 to 
0.93)
0.001 0.87 (0.78 to 
0.97)
0.012
T1 (0.95–6) 229/1476 Ref. Ref. Ref. Ref.
T2 (7, 8) 107/967 0.67 (0.53 to 
0.86)
0.002 0.75 (0.58 to 
0.97)
0.026 0.77 (0.60 to 
0.99)
0.041 0.80 (0.62 to 
1.04)
0.094
T3 (≥ 9) 116/1127 0.63 (0.49 to 
0.81)
< 0.001 0.71 (0.55 to 
0.92)
0.009 0.73 (0.56 to 
0.94)
0.014 0.78 (0.61 to 
1.02)
0.066
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in Table 2. In age and sex adjusted analysis, the OR for 
NAFLD (as estimated by FLI) per 1 SD change in  loge total 
bilirubin was 0.72 (95% CI 0.64–0.80; p < 0.001), which was 
minimally attenuated to 0.77 (95% CI 0.69–0.87; p < 0.001) 
after further adjustment for several established and emerging 
risk factors. Following additional adjustment for hsCRP, the 
OR was 0.82 (95% CI 0.73–0.92; p < 0.001). In analyses that 
compared the top versus bottom tertiles of total bilirubin, 
the inverse associations between total bilirubin and NAFLD 
were evident (Table 2).
Odds ratios for the associations between total biliru-
bin and NAFLD as estimated by the HSI are reported in 
Table 3. The age- and sex-adjusted OR for NAFLD per 
1 SD change in  loge total bilirubin was 0.79 (95% CI 
0.72–0.88; p < 0.001), which remained consistent 0.84 (95% 
CI 0.75–0.93; p = 0.001) following further adjustment for 
several established and emerging risk factors. Following 
additional adjustment for hsCRP, the OR was 0.87 (95% 
CI 0.78–0.97; p = 0.012). In analyses that compared the top 
versus bottom tertiles of total bilirubin, the inverse associa-
tions remained except for evidence of attenuation to the null 
on further adjustment for hsCRP (Table 2).
The association between total bilirubin and NAFLD was 
not statistically significantly modified by sex for both meas-
ures of NAFLD (p > 0.05); whereas the association between 
total bilirubin and NAFLD (as estimated by FLI) was com-
parable in males and females, the age-adjusted inverse asso-
ciation between total bilirubin and NAFLD (as estimated 
by HSI) in males was attenuated to null on further adjust-
ment for established risk factors (Table 4). The ORs for all 
associations remained similar in sensitivity analyses that 
involved exclusion of participants with prevalent diabetes, 
participants on cholesterol lowering medication, or partici-
pants with potential Gilbert’s syndrome (“Appendices 4–5”).
Mendelian randomization findings
There was strong evidence for an association between 
rs6742078 SNP and total bilirubin (0.70 SD increase in total 
bilirubin levels per T allele; SE = 0.03, p = 1.35 × 10−80) and 
the SNP explained 20% of total variance in total bilirubin 
levels. There was no evidence for associations between 
rs6742078 and confounders included in the observational 
analyses, except for a weak association with sex (“Appendix 
Table 4  Association of baseline total bilirubin with incident NAFLD in males and females
CI confidence interval, NAFLD non-alcoholic fatty liver disease, OR odds ratio, SD standard deviation, ORs are reported per 1-SD increase in 
 loge total bilirubin
Model 1: Age
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol
Model 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and  loge urinary albumin excretion
Model 4: Model 3 plus  loge high-sensitivity C-reactive protein
Gender Events/total Model 1 Model 2 Model 3 Model 4
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
NAFLD as measured by Fatty Liver Index
Males 253/1551 0.71 (0.62 to 0.82) < 0.001 0.80 (0.68 to 0.92) 0.002 0.79 (0.68 to 0.92) 0.002 0.81 (0.69 to 0.94) 0.007
Females 181/2273 0.71 (0.59 to 0.85) < 0.001 0.75 (0.63 to 0.90) 0.002 0.75 (0.63 to 0.90) 0.002 0.83 (0.69 to 1.00) 0.055
NAFLD as measured by Hepatic Steatosis Index
Males 358/1591 0.84 (0.72 to 0.97) 0.020 0.92 (0.80 to 1.08) 0.308 0.94 (0.81 to 1.09) 0.407 0.95 (0.81 to 1.11) 0.527
Females 91/1908 0.74 (0.64 to 0.86) < 0.001 0.76 (0.65 to 0.88) < 0.001 0.76 (0.65 to 0.88) < 0.001 0.81 (0.69 to 0.94) 0.006
Table 5  Causal estimates for 
NAFLD (as measured by FLI 
and HSI) using Mendelian 
randomisation analysis
CI confidence interval, FLI fatty liver index, HSI hepatic steatosis index, NAFLD non-alcoholic fatty liver 
disease, OR odds ratio
a Model adjusted for age, sex, smoking status, systolic blood pressure, total cholesterol, high-density lipo-
protein cholesterol, alcohol consumption, glucose, estimated glomerular filtration rate,  loge urinary albu-
min excretion,  loge high-sensitivity C-reactive protein
NAFLD 
outcome
Events/total Unadjusted OR (95% CIs) p value Adjusteda OR (95% CIs) p value
FLI 187/1610 0.98 (0.69 to 1.38) 0.900 0.99 (0.70 to 1.42) 0.978
HSI 190/1528 1.14 (0.81 to 1.59) 0.451 1.10 (0.79 to 1.54) 0.556
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6”). The causal OR for FLI was 0.98 (95% CI 0.69–1.38; 
p = 0.900) per 1 SD genetically elevated total bilirubin level 
and that for HSI was 1.14 (95% CI 0.81–1.59; p = 0.451) 
(Table 5).
Comments
Key findings
Using a large-scale population-based study of predomi-
nantly Caucasian men and women without pre-existing dis-
ease including NAFLD at baseline, we have demonstrated 
that total bilirubin is inversely associated with future risk of 
NAFLD as estimated by two well-known biomarker indices, 
the FLI and HSI respectively. The associations were inde-
pendent of several established risk factors and other poten-
tial confounders and remained robust in several sensitivity 
analyses. The inverse association between total bilirubin and 
NAFLD was not significantly modified by sex. However, 
given the rather relatively small numbers (low event rates) 
in males and females, larger-scale studies in both genders 
are needed to further evaluate a potential role of sex on the 
impact of bilirubin on new onset NAFLD. Furthermore, 
using a MR analysis, we investigated whether the observed 
association between total bilirubin and NAFLD was devoid 
of confounding and/or reverse causation. Despite strong 
observational evidence for associations between biliru-
bin and NAFLD, these results were not supported by MR 
analyses—there was no evidence for a causal relationship 
between genetically elevated bilirubin and NAFLD. While 
the rs6742078 SNP was strongly associated with levels of 
circulating bilirubin and the F statistic (> 400) indicated 
good instrument strength, the observed wide 95% CIs for 
the MR results are indicative of low power. For MR to be 
valid, several assumptions need to be met: [39] the genetic 
instrument (1) must be associated with the exposure of inter-
est, (2) must not be associated with any confounders and 
(3) must not directly influence the outcome, except through 
the exposure of interest. When exploring the association 
between rs6742078 and confounding variables included in 
the observational analyses, no evidence for associations was 
found, except for weak evidence of an association between 
rs6742078 and sex. While this could be a chance finding, 
given the multiple tests that were performed, it is also pos-
sible that this might represent a true causal relationship. This 
might reflect the sex differences in hepatic uridine diphos-
phate glucuronyltransferase (UGT1A1) activity [40], the 
enzyme that contributes substantially to bilirubin glucu-
ronidation and enhances bilirubin elimination. Consistent 
with our findings, previous studies have demonstrated higher 
levels of circulating bilirubin in men compared with women 
[19]. On the contrary, a number of studies have reported 
findings which suggest that the discordance in circulating 
bilirubin levels between males and females may not be 
attributable to differences in the UGT1A1 polymorphism 
[41–43]. Therefore, these findings deserve follow-up in 
larger cohort studies.
Comparison with previous studies
A limited number of epidemiological observational stud-
ies have reported on the associations of bilirubin with the 
risk of NAFLD. In an analysis of over 17,000 participants, 
Kwak et al. demonstrated an inverse association between 
total bilirubin and NAFLD diagnosed on the basis of ultra-
sonographic findings and an alcohol consumption of less 
than 20 g/day [19]. However, the main limitation of this 
study was its cross-sectional design, which precluded the 
ability to assess the temporal relationship between biliru-
bin and the risk of NAFLD. Findings from two prospective 
cohort studies have demonstrated serum direct bilirubin to 
be associated with reduced risk of NAFLD, but found no 
evidence of associations for total or indirect bilirubin [17, 
20]. To our knowledge, this is the first study to demonstrate 
a long-term prospective association between total bilirubin 
and the risk of NAFLD in a general predominantly Cauca-
sian population. We are also the first to investigate whether 
a potential causal association exists between elevated total 
bilirubin levels and decreased NAFLD risk in a general adult 
population. Furthermore, our study employed NAFLD out-
comes diagnosed on the basis of biomarker-based indices, 
whereas previous relevant studies have utilized ultrasono-
graphic findings [17–20].
Potential explanations for findings
Bilirubin, iron and carbon monoxide are degradation prod-
ucts of heme catabolism via heme oxygenase-1 (HO-1) and 
they have been reported to regulate important functions in 
cells [44]. Increasing evidence suggests that bilirubin has 
cytoprotective properties [45], antioxidant actions [13, 
14] and anti-inflammatory effects via its anti-complement 
actions [15, 46]. Since oxidative stress mechanisms and 
inflammation play a major role in the pathophysiology of 
NAFLD [47, 48], if there is a protective effect of bilirubin 
on NAFLD risk, this may be via the potent antioxidant and 
anti-inflammatory effects of bilirubin. Whether total bili-
rubin is a direct cause of NAFLD or just a risk marker of 
underlying NAFLD, is not certain at the moment. Our MR 
findings did not provide evidence for a causal association 
between circulating total bilirubin and NAFLD. It may be 
possible that the observational association may be driven 
by biases such as unmeasured confounding and/or reverse 
causation. The current evidence suggests that total bilirubin 
may just be a risk marker of NAFLD. However, given that 
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the MR estimates were under-powered and a causal effect of 
bilirubin on NAFLD cannot be completely ruled out, further 
investigation in a larger sample is necessary.
Implications of findings
The current findings further contribute to the accumulating 
body of evidence on the putative protective role of bilirubin 
on adverse cardiometabolic outcomes such as hypertension, 
diabetes, metabolic syndrome and CVD [1–4]. Indeed, the 
utility of using circulating bilirubin to prevent and treat car-
diometabolic disease has been extensively debated [23–25]. 
It is reported that patients with Gilbert syndrome (character-
ised by moderate hyperbilirubinaemia) have reduced levels 
of markers of oxidative stress and inflammation and have 
decreased risk of vascular complications; [49, 50] hence, it 
is possible that the sustained hyperbilirubinaemia prevents 
vascular complications via inhibition of oxidative stress and 
inflammation. Circulating bilirubin is a simple, standardised, 
cheap, and easily measured biomarker, hence its potential 
value in reducing the risk of adverse cardiometabolic out-
comes warrants further evaluation.
Strengths and limitations
In addition to the novelty, several strengths of this work 
deserve mention. These include employing a sample that was 
representative of the general population, exclusion of par-
ticipants with pre-existing disease which minimised biases 
due to reverse causation, accounting for several key clinical 
characteristics, and conducting several sensitivity analyses 
to confirm the robustness of the findings. In our MR analy-
sis, we used the rs6742078 variant to examine the potential 
causal relationship, which has been shown to be strongly 
associated with substantial increases in levels of bilirubin 
and explained substantial proportion of variation in biliru-
bin levels. The limitations of the current work include the 
inability to generalise the findings to other populations as the 
sample predominantly comprised of white adults of Dutch 
descent, absence of data on repeat measurements of biliru-
bin to correct for regression dilution bias, and inability to 
replicate or verify the findings in an independent cohort due 
to lack of data. One might say that the association between 
rs6742078 and sex violated one of the conditions for the MR 
analysis, hence impacting on the causal estimates. However, 
this is unlikely for the following reasons: (1) the association 
was weak and (2) it is very likely this was a chance finding 
(due to the multiple statistical tests) given that the rs6742078 
variant has consistently been demonstrated to be very spe-
cific for bilirubin and is not associated with various demo-
graphics (including sex), lifestyle and clinical variables in 
several MR studies [5, 6, 30] and including the PREVEND 
cohort [4] which was employed for these analyses. In addi-
tion, the power to detect an effect similar to the observa-
tional estimates was low and larger samples (with higher 
number of cases) are required. In addition, the availability 
of large samples for genome-wide association study, such 
as UK Biobank [51], will increase the discovery of genetic 
variants, which will in turn provide better instruments for 
MR analyses.
Conclusion
Elevated circulating total bilirubin was independently asso-
ciated with decreased risk of new onset NAFLD in a cohort 
of apparently healthy predominantly Caucasian men and 
women without pre-existing CVD or NAFLD. Based on 
MR analysis, there was little evidence to suggest a causal 
association. The observational association may be driven 
by biases such as unmeasured confounding and/or reverse 
causation. However, due to low statistical power, larger-scale 
investigations are necessary to draw definitive conclusions.
Funding The Dutch Kidney Foundation supported the infrastructure of 
the PREVEND program from 1997 to 2003 (Grant E.033). The Univer-
sity Medical Center Groningen supported the infrastructure from 2003 
to 2006. Dade Behring, Ausam, Roche, and Abbott financed laboratory 
equipment and reagents by which various laboratory determinations 
could be performed. The Dutch Heart Foundation supported studies 
on lipid metabolism (Grant 2001-005). SKK acknowledges support 
from the NIHR Biomedical Research Centre at University Hospitals 
Bristol NHS Foundation Trust and the University of Bristol. The views 
expressed in this publication are those of the authors and not neces-
sarily those of the NHS, the National Institute for Health Research or 
the Department of Health and Social Care. The funding sources had 
no role in study design; in data collection, analysis, or interpretation 
of the data; in writing of the report; or in the decision to submit for 
publication.
Compliance with ethical standards 
Conflict of interest The authors declare they have no conflicts of inter-
est.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
Appendix 1
See Table 6.
Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study:…
1 3
Table 6  STROBE 2007 Statement—Checklist of items that should be included in reports of cohort studies
Section/topic Item # Recommendation Reported on page #
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract
Page 1
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found
Page 2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported
Page 3
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3–4
Methods
Study design 4 Present key elements of study design early in the paper Study population
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection
Study population
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up
Study population
(b) For matched studies, give matching criteria and number of exposed 
and unexposed
Not applicable
Variables 7 Clearly define all outcomes, exposures, predictors, potential confound-
ers, and effect modifiers. Give diagnostic criteria, if applicable
Risk Factor Assessment
Data sources/measurement 8* For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group
Risk Factor Assessment
Bias 9 Describe any efforts to address potential sources of bias Statistical Methods
Study size 10 Explain how the study size was arrived at Statistical Methods
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why
Statistical Methods
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding
Statistical Methods
(b) Describe any methods used to examine subgroups and interactions Statistical Analyses
(c) Explain how missing data were addressed Not applicable
(d) If applicable, explain how loss to follow-up was addressed Not applicable
(e) Describe any sensitivity analyses Statistical Methods
Results
Participants 13* (a) Report numbers of individuals at each stage of study—e.g. num-
bers potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed
Study population
(b) Give reasons for non-participation at each stage Study population
(c) Consider use of a flow diagram
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, 
social) and information on exposures and potential confounders
Results; Table 1; “Appendices 
2–3”
(b) Indicate number of participants with missing data for each variable 
of interest
(c) Summarise follow-up time (e.g. average and total amount) Results
Outcome data 15* Report numbers of outcome events or summary measures over time Results
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (e.g. 95% confidence interval). Make 
clear which confounders were adjusted for and why they were included
Results; Tables 2, 3 and 4
(b) Report category boundaries when continuous variables were catego-
rized
Results; Tables 2, 3 and 4
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, 
and sensitivity analyses
Results; “Appendices 4–5”
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See Table 7.
Table 6  (continued)
Section/topic Item # Recommendation Reported on page #
Discussion
Key results 18 Summarise key results with reference to study objectives Discussion—Summary of main 
findings
Limitations
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence
Discussion
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion
Other information
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based
Pages 14–15
Table 7  Baseline participant 
characteristics according to 
the development of NAFLD as 
measured by FLI
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood 
pressure, eGFR estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epi-
demiology Collaboration combined creatinine-cystatin C equation), FLI fatty liver index, GGT gamma-glu-
tamyltransferase, HDL-C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, 
NAFLD non-alcoholic fatty liver disease
*Employed a two-sample t-tests for a difference in means for continuous variables and a Chi square test for 
categorical variables
Without NAFLD 
(N = 3390)
Mean (SD) or median 
(IQR) or n (%)
With NAFLD (N = 434)
Mean (SD) or median 
(IQR) or n (%)
p value*
Total bilirubin (µmol/l) 7 (5–9) 7 (5–9) < 0.001
Questionnaire
Males 1298 (38.3) 253 (58.3) < 0.001
Age at survey (years) 47 (12) 50 (12) < 0.001
History of diabetes 18 (0.5) 5 (1.2) 0.115
Current and former smokers 2212 (65.3) 303 (69.8) 0.059
Alcohol consumers 2606 (76.9) 332 (76.5) 0.861
Physical measurements
BMI (kg/m2) 24.1 (2.7) 27.1 (2.5) < 0.001
Waist circumference (cm) 81.5 (9.3) 90.9 (7.0) < 0.001
SBP (mmHg) 122 (17) 131 (18) < 0.001
DBP (mmHg) 71 (9) 75 (9) < 0.001
Lipid, metabolic, inflammatory, liver, and renal markers
Total cholesterol (mmol/l) 5.40 (1.07) 5.80 (1.02) < 0.001
HDL-C (mmol/l) 1.45 (0.39) 1.22 (0.32) < 0.001
Triglycerides (mmol/l) 0.95 (0.73–1.26) 1.23 (0.96–1.61) < 0.001
Glucose (mmol/l) 4.57 (0.72) 4.85 (0.76) < 0.001
GGT (U/L) 18 (14–25) 26 (19–36) < 0.001
ALT (U/L) 18 (14–23) 21 (16–28) < 0.001
AST (U/L) 23 (20–26) 24 (21–28) < 0.001
hsCRP (mg/l) 0.84 (0.38–1.96) 1.49 (0.75–3.05) < 0.001
eGFR (ml/min/1.73 m2) 91.2 (15.0) 87.3 (15.0) < 0.001
UAE (mg/24 h) 7.99 (5.84–12.30) 9.42 (6.53–14.61) < 0.001
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See Table 8.
Table 8  Baseline participant 
characteristics according to 
the development of NAFLD as 
measured by HSI
ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, DBP diastolic blood 
pressure, eGFR estimated glomerular filtration rate (as calculated using the Chronic Kidney Disease Epide-
miology Collaboration combined creatinine-cystatin C equation), GGT gamma-glutamyltransferase, HDL-
C high-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, HSI hepatic steatosis 
index, NAFLD non-alcoholic fatty liver disease
*Employed a two-sample t-tests for a difference in means for continuous variables and a Chi square test for 
categorical variables
Without NAFLD 
(N = 3118)
Mean (SD) or median 
(IQR) or n (%)
With NAFLD (N = 452)
Mean (SD) or median 
(IQR) or n (%)
p value*
Total bilirubin (µmol/l) 7 (6–9) 6 (5–9) < 0.001
Questionnaire
Males 1432 (45.9) 195 (43.1) 0.266
Age at survey (years) 47 (12) 48 (12) 0.101
History of diabetes 11 (0.4) 2 (0.4) 0.767
Current and former smokers 2116 (67.9) 306 (67.7) 0.944
Alcohol consumers 2459 (78.9) 322 (71.2) < 0.001
Physical measurements
BMI (kg/m2) 23.7 (2.4) 26.1 (2.0) < 0.001
Waist circumference (cm) 81.8 (10.0) 87.9 (9.5) < 0.001
SBP (mmHg) 123 (18) 128 (19) < 0.001
DBP (mmHg) 72 (9) 73 (9) < 0.001
Lipid, metabolic, inflammatory, liver, and renal markers
Total cholesterol (mmol/l) 5.43 (1.08) 5.69 (1.10) < 0.001
HDL-C (mmol/l) 1.43 (0.40) 1.33 (0.38) < 0.001
Triglycerides (mmol/l) 0.99 (0.74–1.36) 1.15 (0.85–1.63) < 0.001
Glucose (mmol/l) 4.58 (0.70) 4.74 (1.07) < 0.001
GGT (U/L) 19 (14–27) 21 (14–31) < 0.001
ALT (U/L) 17 (14–22) 19 (15–25) < 0.001
AST (U/L) 23 (20–27) 23 (20–28) 0.023
hsCRP (mg/l) 0.84 (0.37–1.99) 1.26 (0.62–2.69) < 0.001
eGFR (ml/min/1.73 m2) 90.8 (15.3) 88.9 (15.1) 0.016
UAE (mg/24 h) 8.28 (5.96–13.13) 8.57 (6.13–12.91) 0.423
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See Table 9.
Table 9  Association of baseline serum total bilirubin levels with FLI in several sensitivity analyses
Gilbert’s disease was defined as total bilirubin > 34.2  µmol/L, aspartate aminotransferase < 80  IU/L, alanine aminotransferase < 80  IU/L, and 
gamma-glutamyltransferase < 80 IU/L
2420 participants with prevalent NAFLD as measured by FLI were excluded
CI confidence interval, FLI fatty liver index, NAFLD non-alcoholic fatty liver disease, OR odds ratio, SD standard deviation, T tertile
Model 1: Age and sex
Model 2: Model 1 plus smoking status, systolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol
Model 3: Model 2 plus alcohol consumption, glucose, estimated glomerular filtration rate, and  loge urinary albumin excretion
Model 4: Model 3 plus  loge high-sensitivity C-reactive protein
Events/total Model 1 Model 2 Model 3 Model 4
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Exclusion of 
people with 
diabetes at 
baseline
429/3801 0.71 (0.63 to 
0.79)
< 0.001 0.77 (0.69 to 
0.86)
< 0.001 0.77 (0.68 to 
0.86)
< 0.001 0.81 (0.72 to 
0.92)
0.001
Exclusion of 
people on 
cholesterol 
lowering medi-
cation
416/3713 0.71 (0.64 to 
0.80)
< 0.001 0.77 (0.69 to 
0.87)
< 0.001 0.77 (0.68 to 
0.87)
< 0.001 0.82 (0.73 to 
0.92)
0.001
Exclusion of 
people with 
potential Gil-
bert’s disease
434/3820 0.72 (0.64 to 
0.80)
< 0.001 0.78 (0.69 to 
0.88)
< 0.001 0.78 (0.69 to 
0.87)
< 0.001 0.82 (0.73 to 
0.93)
0.001
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See Table 11.
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